<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), a germinal center B-cell-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, the pro-apoptotic properties of c-MYC must be counterbalanced </plain></SENT>
<SENT sid="1" pm="."><plain>Predicting that survival signals would be delivered by <z:chebi fb="0" ids="16749">phosphoinositide</z:chebi>-3-kinase (PI3K), a major survival determinant in mature B cells, we indeed found that combining constitutive c-MYC expression and PI3K activity in germinal center B cells of the mouse led to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-like <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, which fully phenocopy human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> with regard to histology, surface and other markers, and gene expression profile </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> also accumulate tertiary mutational events, some of which are recurrent in the human disease </plain></SENT>
<SENT sid="3" pm="."><plain>These results and our finding of recurrent PI3K pathway activation in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> indicate that deregulated c-MYC and PI3K activity cooperate in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> pathogenesis </plain></SENT>
</text></document>